Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta‐analysis of randomised controlled trials

  title={Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta‐analysis of randomised controlled trials},
  author={S. L. Han and Shuang-lin Wan},
  journal={International Journal of Clinical Practice},
  • S. Han, S. Wan
  • Published 1 February 2012
  • Medicine
  • International Journal of Clinical Practice
To determine the efficacy of teriparatide supplementation for improving bone mineral density (BMD) and fracture risk in postmenopausal osteoporosis and if effects vary with factors. We identified eight randomised controlled trials (n = 2388) using electronic databases, supplemented by a hand‐search of the reference lists. All trials aimed to evaluate the efficacy of daily subcutaneous teriparatide injection in postmenopausal osteoporosis. The main outcomes were fracture risk and percentage… 
Comparison between teriparatide and bisphosphonates for improving bone mineral density in postmenopausal osteoporosis patients
Teriparatide significantly reduced the occurrence of vertebral and nonvertebral fractures in osteoporosis patients and more studies should focus on the quality of life of patients using these 2 drugs.
Efficacy of Non-Bisphosphonates for Prevention of Osteoporotic Vertebral Fracture in Postmenopausal Women: A Systematic Review and Meta-Analysis
Non-bisphosphonate drugs including denosumab, strontium ranelate and teriparatide were efficacious in preventing osteoporotic vertebral fracture in post-menopausal women, however, evidences indicating efficacy of raloxifene and tibolone were limited; the use of these drugs should be cautious.
Head-to-head comparisons of bisphosphonates and teriparatide in osteoporosis: a meta-analysis.
Teriparatide significantly increased the BMD of lumbar spine, total hip and femoral neck, particularly in GIO-induced osteoporosis, and did not lower the risk of nonvertebral fractures when compared with bisphosphonates.
Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis
Teriparatide may be superior to alendronate for increasing lumbar spine BMD in postmenopausal osteoporosis and the efficacy and safety of long-term teriparatides and alendronsate treatment in post menopausal osteopsorosis should be further investigated in clinical trials.
A systematic review on the use of daily subcutaneous administration of teriparatide for treatment of patients with osteoporosis at high risk for fracture in Asia
The clinical effectiveness of teriparatide for treatment of postmenopausal women with osteoporosis who are at high risk of fracture in Asia is focused primarily on improvements in BMD and tolerability.
Clinical Application of Teriparatide in Fracture Prevention: A Systematic Review
Teriparatide was safe and was not associated with an increased rate of adverse events when compared with other drugs, and was effective for the Prevention of vertebral and overall nonvertebral fractures in osteoporotic patients but not for the prevention of site-specific nonverTEbral fractures at the wrist and hip.
Skeletal response to treatment with teriparatide (TPD) after bisphosphonate in post-menopausal women with osteoporosis and a high prevalence of secondary risk factors in real-life setting of a metabolic bone clinic; effect of age and vitamin D status
Vitamin D status may influence the early anabolic effect to teriparatide and may be important considerations when initiating and optimising treatment with TPD, although further larger studies are needed to confirm these findings.


Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study
The results observed in Japanese patients may support the observation that teriparatide stimulates bone formation in patients with osteoporosis at a high risk of fracture, and suggest a persistent, positive, balanced anabolic effect of terIParatide.
Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Results show that teriparatide is an effective and safe drug in increasing the BMD and therefore, teriparide provides yet another new therapeutic option for reducing the risk management of osteoporosis in postmenopausal women.
Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk – a meta-analysis
It is revealed that PTH alone or in combination with antiresorptive drugs would appear to be able to reduce the risk of vertebral and non-vertebral fractures and to increase spine and perhaps hip BMD.
Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.
Vertebral fracture risk reduction by teriparatide administration persists for at least 18 months after discontinuation of therapy, and post hoc analysis suggests that teripararatide treatment substantially reduced the increased risk of subsequent fracture in women who sustained a fracture during the FPT.
Teriparatide (recombinant human parathyroid hormone 1-34) in postmenopausal women with osteoporosis: systematic review.
When teriparatide is intermittently administered in low doses, it reduces the incidence of vertebral fractures and non-vertebral fractures, and increases bone mineral density in the lumbar column and femur.
Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis
This systematic review found good evidence that multiple agents, including alendronate, zoledronic acid, and estrogen, prevented vertebral and hip fractures more than placebo.
Effects of Two Years of Daily Teriparatide Treatment on BMD in Postmenopausal Women With Severe Osteoporosis With and Without Prior Antiresorptive Treatment
Prior AR treatment modestly blunted the BMD response to teriparatide, resulting in a significant increase in BMD in patients with and without previous AR use.
Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis.
Alendronate reduces the ability of teriparatide to increase BMD and bone turnover in women.
Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.
There is as yet no evidence that the antifracture efficacy of PTH will be superior to the bisphosphonates, whereas cost-utility estimates suggest that teriparatide is significantly more expensive.